Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

References

• Klimstra David SYZ. Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system In: Goldberg Richard MSDM, editor. Waltham, MA: UpToDate; 2018.
   Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. doi:10.1001/jamaoncol.2017.058928448665
   PubMed Web of Science ®Google Scholar
• Ohike NAN. Mixed neuroendocrine-non-neuroendocrine neoplasms In: Lloyd RVOR, editor. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017:238.
   Google Scholar
• Vinik AI, Woltering EA, Warner RRP, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713–734. doi:10.1097/MPA.0b013e3181ebaffd20664471
   PubMed Web of Science ®Google Scholar
• Halperin DM, Shen C, Dasari A, et al. The frequency of carcinoid syndrome at neuroendocrine tumor diagnosis: a large population-based study using SEER-medicare data. Lancet Oncol. 2017;18(4):525–534. doi:10.1016/S1470-2045(17)30072-428238592
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016;17(18):2487–2498. doi:10.1517/14656566.2016.112940227817224
   PubMed Web of Science ®Google Scholar
• Boutzios G, Kaltsas G. Clinical syndromes related to gastrointestinal neuroendocrine neoplasms. Front Horm Res. 2015;44:40–57.26303703
   PubMed Web of Science ®Google Scholar
• Druce M, Rockall A, Grossman AB. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol. 2009;5(5):276–283. doi:10.1038/nrendo.2009.5119444261
   PubMed Web of Science ®Google Scholar
• Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:662. doi:10.3332/ecancer.2016.66227594907
   PubMedGoogle Scholar
• Zacks J, Lavine R, Ratner L, Warner R. Telotristat etiprate appears to halt carcinoid heart disease. Neuroendocrinology. 103(suppl 1):90.
   Google Scholar
• Dobson R, Burgess MI, Banks M, et al. The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: a cross-sectional study Holvoet P, editor PLoS One. 2013; 8(9):e73679. doi:10.1371/journal.pone.007367924069222
   PubMed Web of Science ®Google Scholar
• Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348(11):1005–1015. doi:10.1056/NEJMicm02003712637610
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–588. doi:10.1056/NEJM1997082833709019271479
   PubMed Web of Science ®Google Scholar
• Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004;90(10):1224–1228. doi:10.1136/hrt.2004.04032915367531
   PubMed Web of Science ®Google Scholar
• Dobson R, Burgess MI, Valle JW, et al. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer. 2014;111(9):1703–1709. doi:10.1038/bjc.2014.34825211656
   PubMed Web of Science ®Google Scholar
• Plockinger U, Gustafsson B, Ivan D, Szpak W, Davar J. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography. Neuroendocrinology. 2009;90(2):190–193. doi:10.1159/00022594719713710
   PubMed Web of Science ®Google Scholar
• Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461–466. doi:10.1097/MPA.0b013e318232804522422138
   PubMed Web of Science ®Google Scholar
• Haugland T, Vatn MH, Veenstra M, Wahl AK, Natvig GK. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res. 2009;18(6):719–726. doi:10.1007/s11136-009-9478-y19479341
   PubMed Web of Science ®Google Scholar
• Frojd C, Larsson G, Lampic C, von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;11(5):18. doi:10.1186/1477-7525-5-18
   Google Scholar
• Lamarca A, McCallum L, Nuttall C, et al. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Rev Gastroenterol Hepatol. 2018;12(7):723–731. doi:10.1080/17474124.2018.148923229923433
   PubMed Web of Science ®Google Scholar
• Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016;24(9):3695–3703. doi:10.1007/s00520-016-3189-z27029477
   PubMed Web of Science ®Google Scholar
• Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017;3(1):43–53. doi:10.1200/JGO.2015.00298028717741
   PubMed Web of Science ®Google Scholar
• Wolin EM, Leyden J, Goldstein G, Kolarova T, Hollander R, Warner RRP. Patient-reported experience of diagnosis, management, and burden of neuroendocrine tumors: results from a large patient survey in the United States. Pancreas. 2017;46(5):639–647. doi:10.1097/MPA.000000000000081828328615
   PubMed Web of Science ®Google Scholar
• Wymenga AN, de Vries EG, Leijsma MK, Kema IP, Kleibeuker JH. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer. 1998;34(8):1293–1294. doi:10.1016/S0959-8049(98)00009-49849494
   PubMed Web of Science ®Google Scholar
• Kiesewetter B, Duan H, Lamm W, et al. Oral ondansetron offers effective antidiarrheal activity for carcinoid syndrome refractory to somatostatin analogs. Oncologist. 2019;24(2):255–258. doi:10.1634/theoncologist.2018-019130171068
   PubMed Web of Science ®Google Scholar
• Niederle B, Pape U-F, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016;103(2):125–138. doi:10.1159/00044317026758972
   PubMed Web of Science ®Google Scholar
• Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, GA F; ELECT Study Group. Evaluation of lanreotide Depot/autogel Efficacy And Safety As A Carcinoid Syndrome Treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068–1080. doi:10.4158/1934-2403-22.12.e127214300
   PubMed Web of Science ®Google Scholar
• Fisher GA, Wolin EM, Liyanage N, et al. Lanreotide therapy in carcinoid syndrome: prospective analysis of patient-reported symptoms in patients responsive to prior octreotide therapy and patients naïve to somatostatin analogue therapy in the elect phase 3 study. Endocr Pract. 2018;24(3):243–255. doi:10.4158/EP172000.OR29547049
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–188.19845567
   PubMed Web of Science ®Google Scholar
• Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000;23(4):412–415. doi:10.1097/00000421-200008000-0002010955874
   PubMed Web of Science ®Google Scholar
• Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663–666. doi:10.1056/NEJM1986091131511022427948
   PubMed Web of Science ®Google Scholar
• Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17(4):1111. doi:10.1200/JCO.1999.17.4.111110561168
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47. doi:10.1210/er.2000-000112588807
   PubMed Web of Science ®Google Scholar
• Carmona-Bayonas A, Jimenez-Fonseca P, Custodio A, et al. Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 2017;19(11):72. doi:10.1007/s11912-017-0633-228920153
   PubMed Web of Science ®Google Scholar
• Molina-Cerrillo J, Alonso-Gordoa T, Martinez-Saez O, Grande E. Inhibition of peripheral synthesis of serotonin as a new target in neuroendocrine tumors. Oncologist. 2016;21(6):701–707. doi:10.1634/theoncologist.2015-033627107003
   PubMed Web of Science ®Google Scholar
• Cordoba-Chacon J, Gahete MD, Duran-Prado M, et al. Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci. 2010;67(7):1147–1163. doi:10.1007/s00018-010-0401-z20063038
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663. doi:10.1200/JCO.2009.22.851019704057
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233. doi:10.1056/NEJMoa141049025014687
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930–936. doi:10.1634/theoncologist.2014-012025096997
   PubMed Web of Science ®Google Scholar
• Kvols LK, Oberg KE, O’Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657–666. doi:10.1530/ERC-11-036222807497
   PubMed Web of Science ®Google Scholar
• Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075–5086. doi:10.2147/DDDT.S84177
   PubMed Web of Science ®Google Scholar
• Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2017;18(12):1652–1664. doi:10.1016/S1470-2045(17)30072-429074099
   PubMed Web of Science ®Google Scholar
• Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2017;28(6):1309–1315. doi:10.1093/annonc/mdx07528327907
   PubMed Web of Science ®Google Scholar
• Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983;309(3):129–133. doi:10.1056/NEJM1983072130903016191217
   PubMed Web of Science ®Google Scholar
• Smith DB, Scarffe JH, Wagstaff J, Johnston RJ. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep. 1987;71(12):1265–1266.3690534
   PubMedGoogle Scholar
• Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol. 1989;7(7):865–868. doi:10.1200/JCO.1989.7.7.8652738623
   PubMed Web of Science ®Google Scholar
• Valimaki M, Jarvinen H, Salmela P, Sane T, Sjoblom SM, Pelkonen R. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer. 1991;67(3):547–549. doi:10.1002/1097-0142(19910101)67:1<126::aid-cncr2820670123>3.0.co;2-71702352
   PubMed Web of Science ®Google Scholar
• Veenhof CH, de Wit R, Taal BG, et al. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Eur J Cancer. 1992;28(1):75–78. doi:10.1016/0959-8049(92)90389-J1373635
   PubMedGoogle Scholar
• Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32(2):225–229. doi:10.3109/028418693090839167686765
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo M, Bajetta E, Zilembo N, et al. Treatment of carcinoid syndrome with recombinant interferon alpha-2a. Acta Oncol. 1993;32(2):235–238. doi:10.3109/028418693090839187686766
   PubMed Web of Science ®Google Scholar
• Yao JC, Guthrie KA, Moran C, et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol. 2017;35(15):1695–1703. doi:10.1200/JCO.2016.70.407228384065
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet (London, England). 2011;378(9808):2005–2012. doi:10.1016/S0140-6736(11)60984-7
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523. doi:10.1056/NEJMoa100799421306238
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet (London, England). 2016;387(10022):968–977. doi:10.1016/S0140-6736(15)00817-X
   PubMed Web of Science ®Google Scholar
• Pavel M, Unger N, Borbath I, et al. Safety and QOL in patients with advanced NET in a phase 3b expanded access study of everolimus. Target Oncol. 2016;11(5):667–675. doi:10.1007/s11523-016-0440-y27193465
   PubMed Web of Science ®Google Scholar
• Bainbridge HE, Larbi E, Middleton G. Symptomatic control of neuroendocrine tumours with everolimus. Horm Cancer. 2015;6(5–6):254–259. doi:10.1007/s12672-015-0233-226245686
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513. doi:10.1056/NEJMoa100799421306237
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326(8):519–523. doi:10.1056/NEJM1992022032608041310159
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762–4771. doi:10.1200/JCO.2004.08.04015570077
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–275. doi:10.1002/cncr.2542520824724
   PubMed Web of Science ®Google Scholar
• Meyer T, Qian W, Caplin ME, et al. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer. 2014;50(5):902–911. doi:10.1016/j.ejca.2013.12.01124445147
   PubMed Web of Science ®Google Scholar
• Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663–670. doi:10.1007/s00280-012-2055-z23370660
   PubMed Web of Science ®Google Scholar
• Lamarca A, Elliott E, Barriuso J, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause? Cancer Treat Rev. 2016;44:26–41. doi:10.1016/j.ctrv.2016.01.00526855376
   PubMed Web of Science ®Google Scholar
• Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135. doi:10.1056/NEJMoa160742728076709
   PubMed Web of Science ®Google Scholar
• Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36(25):2578–2584. doi:10.1200/JCO.2018.78.586529878866
   PubMed Web of Science ®Google Scholar
• Matthes S, Bader M. Peripheral serotonin synthesis as a new drug target. Trends Pharmacol Sci. 2018;39(6):560–572. doi:10.1016/j.tips.2018.03.00429628275
   PubMed Web of Science ®Google Scholar
• Fidalgo S, Ivanov DK, Wood SH. Serotonin: from top to bottom. Biogerontology. 2013;14(1):21–45. doi:10.1007/s10522-012-9406-323100172
   PubMed Web of Science ®Google Scholar
• Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science (New York, NY). 2003;299(5603):76. doi:10.1126/science.1078197
   Google Scholar
• Adaway J, Dobson R, Walsh J, et al. Serum 5HIAA: a better biomarker than urine for detecting and monitoring neuroendocrine tumours? BioScientifica. 2014 [cited January 16, 2019] Available from: https://www.endocrine-abstracts.org/ea/0034/ea0034p45. Accessed June 24, 2019.
   Google Scholar
• European Medicines Agency. Xermelo [Internet]. 2017 [cited 928, 2018]. Available from: https://www.ema.europa.eu/documents/assessment-report/xermelo-epar-public-assessment-report_en.pdf. Accessed 624, 2019.
   Google Scholar
• Margolis KG, Stevanovic K, Li Z, et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut. 2014;63(6):928–937. doi:10.1136/gutjnl-2013-30490123749550
   PubMed Web of Science ®Google Scholar
• Engelman K, Lovenberg W, Sjoerdsma A. Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. N Engl J Med. 1967;277(21):1103–1108. doi:10.1056/NEJM1967112327721016054996
   PubMed Web of Science ®Google Scholar
• A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Determine the Safety and Tolerability of Orally Administered LX1606 in Healthy Human Subjects. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; 2008.
   Google Scholar
• Lapuerta P, Zambrowicz B, Fleming D, Wheeler D, Arthur S. Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome. Clin Invest (Lond). 2015;5:447–456. doi:10.4155/cli.15.10
   Google Scholar
• Pavel M, Horsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–1519. doi:10.1210/jc.2014-394125636046
   PubMed Web of Science ®Google Scholar
• Kulke MH, O’Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705–714. doi:10.1530/ERC-14-017325012985
   PubMed Web of Science ®Google Scholar
• Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23. doi:10.1200/JCO.2016.69.278027918724
   PubMed Web of Science ®Google Scholar
• Pavel M, Gross DJ, Benavent M, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309–322. doi:10.1530/ERC-17-045529330194
   PubMed Web of Science ®Google Scholar
• Hörsch D, Rocio Garcia-Carbonero JW, Valle PP, et al. Efficacy and safety of telotristat ethyl in combination with lanreotide in patients with a neuroendocrine tumour and carcinoid syndrome diarrhoea: meta-analysis of phase 3 double-blind placebo-controlled TELESTAR and TELECAST studies. Ann Oncol. 2018;29(suppl_8):viii467–78. doi:10.1093/annonc/mdx807
   Google Scholar
• Markham A. Telotristat ethyl: first global approval. Drugs. 2017;77(7):793–798. doi:10.1007/s40265-017-0731-328382568
   PubMed Web of Science ®Google Scholar
• Oates JA, Melmon K, Sjoerdsma A, Gillespie L, Mason DT. Release of a kinin peptide in the carcinoid syndrome. Lancet. 1964;1(7332):514–517. doi:10.1016/S0140-6736(64)92907-114100182
   PubMedGoogle Scholar
• Norheim I, Theodorsson-Norheim E, Brodin E, Oberg K. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab. 1986;63(3):605–612. doi:10.1210/jcem-63-3-6052426299
   PubMed Web of Science ®Google Scholar
• Cunningham JL, Janson ET, Agarwal S, Grimelius L, Stridsberg M. Tachykinins in endocrine tumors and the carcinoid syndrome. Eur J Endocrinol. 2008;159(3):275–282. doi:10.1530/EJE-08-027118524798
   PubMed Web of Science ®Google Scholar
• Gelhorn HL, Kulke MH, O’Dorisio T, et al. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clin Ther. 2016;38(4):759–768. doi:10.1016/j.clinthera.2016.03.00227041406
   PubMed Web of Science ®Google Scholar
• Anthony L, Ervin C, Lapuerta P, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–2168. doi:10.1016/j.clinthera.2017.09.01329074312
   PubMed Web of Science ®Google Scholar
• Weickert MO, Kaltsas G, Horsch D, et al. Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome. Clin Ther. 2018;40(6):952–962.e2. doi:10.1016/j.clinthera.2018.04.00629724499
   PubMed Web of Science ®Google Scholar
• Scott Neil W, Fayers Peter M, Aaronson Neil K, et al. EORTC QLQ-C30 Reference values [Internet]. 2008 [cited 1015, 2018]. Available from: http://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf. Accessed 624, 2019.
   Google Scholar
• Oberg K, Janson ET, Eriksson B. Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S160–S162.10604122
   PubMedGoogle Scholar
• Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(Suppl 1):33–38. doi:10.1159/00005185310940685
   PubMedGoogle Scholar
• Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006;13(2):67–76.17576444
   PubMedGoogle Scholar
• Feinberg Y, Law C, Singh S, Wright FC. Patient experiences of having a neuroendocrine tumour: a qualitative study. Eur J Oncol Nurs. 2013;17(5):541–545. doi:10.1016/j.ejon.2013.02.00323522828
   PubMed Web of Science ®Google Scholar
• Goldstein G, Evans K, Shah A, Lapuerta P. Carcinoid syndrome impact survey: evaluation of the burden of illness and the gap between patient and oncologist perceptions. J Clin Oncol. 2017;35:8_suppl.
   Web of Science ®Google Scholar
• Yoo H, Shin DW, Jeong A, et al. Perceived social support and its impact on depression and health-related quality of life: a comparison between cancer patients and general population. Jpn J Clin Oncol. 2017;47(8):728–734. doi:10.1093/jjco/hyx06428531292
   PubMed Web of Science ®Google Scholar
• Hinz A, Mehnert A, Degi C, Reissmann DR, Schotte D, Schulte T. The relationship between global and specific components of quality of life, assessed with the EORTC QLQ-C30 in a sample of 2019 cancer patients. Eur J Cancer Care (Engl). 2017;26:2. doi:10.1111/ecc.12416
   Web of Science ®Google Scholar
• Jimenez-Fonseca P, Carmona-Bayonas A, Martin-Perez E, et al. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2015;34(3):381–400. doi:10.1007/s10555-015-9573-126245646
   PubMed Web of Science ®Google Scholar
• Ramage JK, Davies AH. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer. 2003;10(4):483–486. doi:10.1677/erc.0.010048314713261
   PubMed Web of Science ®Google Scholar
• Chau I, Casciano R, Willet J, Wang X, Yao JC. Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. Eur J Cancer Care (Engl). 2013;22(6):714–725. doi:10.1111/ecc.2013.22.issue-623895457
   PubMed Web of Science ®Google Scholar
• Martini C, Gamper E-M, Wintner L, et al. Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes. 2016;14(1):127. doi:10.1186/s12955-016-0426-627614762
   PubMedGoogle Scholar
• Vinik E, Silva MP, Vinik AI. Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):97–109, viii. doi:10.1016/j.ecl.2010.12.00821349413
   PubMed Web of Science ®Google Scholar
• Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38(Suppl 4):S125–S133.11858978
   PubMed Web of Science ®Google Scholar
• Davies AHG, Larsson G, Ardill J, et al. Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer. 2006;42(4):477–484. doi:10.1016/j.ejca.2005.10.02516412628
   PubMed Web of Science ®Google Scholar
• Yadegarfar G, Friend L, Jones L, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108(2):301–310. doi:10.1038/bjc.2012.49423322194
   PubMed Web of Science ®Google Scholar
• Vinik E, Carlton CA, Silva MP, Vinik AI. Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas. 2009;38(3):e87–e95. doi:10.1097/MPA.0b013e31819b644119276865
   PubMed Web of Science ®Google Scholar
• Lamarca A, Ronot M, Moall S, et al. Tumour growth rate (TGR) in neuroendocrine tumours (NETs): changes following systemic treatment; the GREPONET-2 study [Internet]; 2019. doi:10.1634/theoncologist.2018-0672
   Google Scholar
• Siddiqui EJ, Thompson CS, Mikhailidis DP, Mumtaz FH. The role of serotonin in tumour growth (review). Oncol Rep. 2005;14(6):1593–1597.16273262
   PubMed Web of Science ®Google Scholar
• Jiang S-H, Li J, Dong F-Y, et al. Increased serotonin signaling contributes to the Warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice. Gastroenterology. 2017;153(1):277–291.e19. doi:10.1053/j.gastro.2017.03.00828315323
   PubMed Web of Science ®Google Scholar
• Alpini G, Invernizzi P, Gaudio E, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 2008;68(22):9184–9193. doi:10.1158/0008-5472.CAN-08-213319010890
   PubMed Web of Science ®Google Scholar
• Svejda B, Kidd M, Timberlake A, et al. Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors. Cancer Sci. 2013;104(7):844–855. doi:10.1111/cas.1217423578138
   PubMed Web of Science ®Google Scholar
• Svejda B, Kidd M, Giovinazzo F, et al. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer. 2010;116(12):2902–2912. doi:10.1002/cncr.2504920564397
   PubMed Web of Science ®Google Scholar
• Drozdov I, Kidd M, Gustafsson BI, et al. Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer. 2009;115(21):4934–4945. doi:10.1002/cncr.2453319634160
   PubMed Web of Science ®Google Scholar
• Vicaut E, Laemmel E, Stucker O. Impact of serotonin on tumour growth. Ann Med. 2000;32(3):187–194. doi:10.3109/0785389000899882610821326
   PubMed Web of Science ®Google Scholar
• Vinik A, Bottomley A, Korytowsky B, et al. Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial. Target Oncol. 2016;11(6):815–824. doi:10.1007/s11523-016-0462-527924459
   PubMed Web of Science ®Google Scholar
• Fjallskog M-LH, Janson ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology. 2008;88(1):53–58. doi:10.1159/00011757518285678
   PubMed Web of Science ®Google Scholar